The Tuberous Sclerosis Complex Research Program (TSCRP) is now accepting Pre-Applications for the fiscal year 2019 grant cycle.
Three award mechanisms are available this year:
- Exploration – Hypothesis Development Award (up to $150,000 in direct costs over two years)
- Idea Development Award (up to $450,000 in direct costs over three years)
- Clinical Translational Research Award (up to $600,000 in direct costs over three years)
The deadline to submit a Pre-Application Letter of Intent has been extended to July 9, 2019 at 5 p.m. Eastern Time (ET). A brief summary of the three award mechanisms and submission requirements can be found here.
The goal of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (TSC), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public. Within this context, the FY19 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY19 Focus Areas:
- Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
- Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
- Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions
- Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinicalpharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization
TSCRP is part of the Congressionally Directed Medical Research Programs (CDMRPs) at the United States Department of Defense. Please see the TSCRP website for more information on these three funding mechanisms.